Mira Pharmaceuticalsの空売り状況は、投資家がMira Pharmaceuticalsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Mira Pharmaceuticals (NASDAQ:MIRA) 株価情報, 空売り情報

Mira Pharmaceuticals

Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals Inc

MIRAI Corp

MIRAIT One Corp

MIRAMAR RESOURCES LTD by MIRAMAR RESOURCES LTD

MIRATI THERAPEUTICS INC COM

MIRACLE ENTMT INC by Miracle Entertainment Inc.

Miracle Entertainment Inc

MIRAGE ENERGY CORP by Mirage Energy Corporation

Mirage Energy Corp

MIRAMAR HOTE & INVST CO by Miramar Hotel & Investment Co., Ltd.

Miramar Hotel & Investment Co Ltd

TAKARA LEBEN CO LTD by Takara Leben Co., Ltd.

Mirarth Holdings Inc

MIRASOL RESOURCES LTD by Mirasol Resources Ltd.

Mirasol Resources Ltd

Miratap Inc

MIRAVANT MEDICAL TECHS by Miravant Medical Technologies

Miravant Medical Technologies

WIIM

Iamgold shares are trading lower after the company reported worse-than-expected Q1 sales results.

Baird analyst Michael Bellisario maintains Marriott International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) with a Neutral and raises the price target from $250 to $265.

News

Price Target

Analyst Ratings

Baird Maintains Neutral on Marriott International, Raises Price Target to $265

Telsey Advisory Group analyst Cristina Fernandez reiterated a Market Perform rating on Under Armour Inc.&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) <a href="https://www.benzinga.com/quote/UAA/analyst-ratings">shares on Wednesday</a>.
She lowered the price forecast from $10.00 to $7.00.
The company is scheduled to report fourth-quarter FYF25 earnings on Tuesday, May 13 before the markets open.
Ahead of Under Armour&#8217;s upcoming fourth-quarter FY25 results next week, the analyst&#8217;s focus will be on several key areas: underlying demand patterns during the quarter and expectations moving into FY26, how consumers are responding to new product offerings, 
The brand must also address tariff pressures, mainly 10% duties from Asian regions. The brand has minimal exposure (around 3%) to Chinese imports.
Also Read: <a href="https://www.benzinga.com/25/05/45237060/despite-nikes-executive-overhaul-ongoing-challenges-persist-says-analyst">Nike Revamps C-Suite, &#8216;Win Now&#8217; Strategy Faces Profit Pressure: Analyst</a>
Fernandez has trimmed FY26 estimates. She lowered her EPS estimate to 35 cents from 40 cents (FS $0.36), with a revenue decline of 1.3% vs. 0.7% previously (FS -0.4%). Operating margins should expand ~50 bps to 4.3% vs. 4.9% previously (FS 4.1%), she added.
Fernandez also anticipates continued sales softness in the first half of fiscal 2026. Under Armour is working to streamline SKUs and reduce discounting in both the North American and Asia-Pacific (APAC) markets.
The analyst sees room for recovery by Q4 of 2026, supporting the forecast for a 1.3% overall revenue decline. This is paired with a 50 basis point improvement in operating margin, bringing it to 4.3%.
The company boosted its 2025 EPS outlook, but revenue growth remains uncertain. Challenges in North America and APAC remain, as well as intense competition and cautious consumer behavior.
To become more optimistic about the stock, the analyst needs more details on distribution strategies.
Price Action: Under Armour shares traded lower by 0.70% at $5.65 at last check Wednesday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/25/05/45251112/coty-stock-slips-as-revenue-misses-outlook-cut-despite-operating-profit-gains">Coty Stock Slips As Revenue Misses, Outlook Cut Despite Operating Profit Gains</a></li>
</ul>
Image: Shutterstock

Reiteration

General

Under Armour Faces Tough Road Ahead, Says Analyst

Baird analyst Craig Kennison maintains LCI Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LCII#NYSE">LCII</a>) with a Neutral and lowers the price target from $100 to $95.

LCII

Baird Maintains Neutral on LCI Industries, Lowers Price Target to $95

Shares of food and personal-care company&nbsp;Hain Celestial Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAIN#NASDAQ">HAIN</a>) are <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">trading lower</a> on Wednesday following the third-quarter earnings result.
The company <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45248205/hain-celestial-reports-fiscal-third-quarter-2025-financial-results" rel="noreferrer noopener">reported a third-quarter FY25 revenue</a> decline of 11% year-on-year to $390.35 million, missing the analyst consensus estimate of $4411.62 million. Adjusted EPS of $0.07 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">missed the consensus</a> estimate of $0.13.
Organic&nbsp;net sales from North America decreased 10% Y/Y, primarily driven by lower sales in snacks and baby &amp; kids.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/restaurants/25/05/45177147/mcdonalds-stumbles-on-weak-traffic-despite-margin-gains-and-analyst-optimism" rel="noreferrer noopener">McDonald's Stumbles On Weak Traffic, Despite Margin Gains And Analyst Optimism</a>
International organic&nbsp;sales gained 0.5%, driven by growth in meal prep and baby &amp; kids and the supply chain recovery from the service issues discussed last quarter.
The Terra Chips maker adjusted gross margin for the quarter contracted 50 basis points Y/Y to 21.8%. The operating loss for the quarter was $121.1 million versus a loss of $27.9 million last year.
Adjusted EBITDA was&nbsp;$34 million&nbsp;compared to&nbsp;$44 million&nbsp;in the prior year period. The adjusted EBITDA margin was&nbsp;8.6%, compared to&nbsp;10%&nbsp;in the prior year.
The company held $44.4 million in cash and equivalents as of March 31, 2025. Operating cash flow for the quarter was $5 million, with a free cash flow of $(2) million.
Net debt at the end of the fiscal&nbsp;second quarter&nbsp;was&nbsp;$665 million&nbsp;compared to&nbsp;$690 million&nbsp;at the beginning of the fiscal year.
<h2 class="wp-block-heading">CEO Transition</h2>
Hain announced that Wendy Davidson <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45248055/the-hain-celestial-group-announces-ceo-transition-and-strategic-review-of-portfolio" rel="noreferrer noopener">will depart as</a> President, Chief Executive Officer and member of the Board of Directors, effective Wednesday.
"We are disappointed with our third quarter results, which fell far short of our expectations primarily due to worse-than-expected performance in North America," stated&nbsp;Interim President and CEO Alison Lewis.
<h2 class="wp-block-heading">Business Strategic Review</h2>
Hain also said that the Board is conducting a comprehensive review of the company's portfolio with the assistance of its independent financial advisor, Goldman Sachs &amp; Co.&nbsp;
"Going forward, we are focused on five key drivers for improving value: simplifying our business and reducing overhead spending, accelerating renovation and innovation in our brands, implementing strategic revenue growth management and pricing actions, driving operational productivity and working capital reduction, and strengthening our digital capabilities."
<h2 class="wp-block-heading">Outlook For FY25</h2>
Hain Celestial expects FY25 organic net sales to decline 5% &#8211; 6%.
Adjusted EBITDA is expected to be approximately $125 million. Gross margin is expected to be approximately 21.5%.
Hain sees free cash flow of about $40 million.
Price Action: HAIN shares traded lower by 49.50% to $1.40 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45237060/despite-nikes-executive-overhaul-ongoing-challenges-persist-says-analyst" target="_blank" rel="noreferrer noopener">Nike Revamps C-Suite, ‘Win Now' Strategy Faces Profit Pressure: Analyst</a></li>
</ul>
Photo by Joni Hanebutt via Shutterstock

Earnings

Guidance

Asset Sales

Management

Movers

HAIN

Terra Chips Maker Hain Celestial Seeks Strategic Options For Business, Announces CEO Transition, Stock Tanks

ANET

Arista Networks shares are trading lower after Goldman Sachs and Needham cut their respective price targets on the stock.

BABA

BIDU

BILI

HSAI

XPEV

Shares of US-listed Chinese stocks are trading lower after two senior US lawmakers called on the SEC to delist 25 Chinese companies from US stock exchanges,

Baird analyst Timothy Wojs maintains Fortune Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBIN#NYSE">FBIN</a>) with a Neutral and lowers the price target from $56 to $54.

FBIN

Baird Maintains Neutral on Fortune Brands, Lowers Price Target to $54

RBC Capital analyst Ken Herbert maintains Leidos Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) with a Sector Perform and raises the price target from $150 to $160.

LDOS

RBC Capital Maintains Sector Perform on Leidos Holdings, Raises Price Target to $160

Hims &amp; Hers Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares have surged 32% to $50.48 since Tuesday's session open, following the company&#8217;s first-quarter <a href="https://www.benzinga.com/quote/HIMS/earnings">earnings</a> report released late Monday.
What To Know: The telehealth company posted first-quarter revenue of <a href="https://www.benzinga.com/general/health-care/25/05/45208186/hims-hers-health-q1-earnings-revenue-jumps-111-subscribers-up-38-q2-guidance-falls-short-of-estimates-shares-slide">$586.01 million</a>, exceeding analyst expectations of $538.2 million and marking a 111% year-over-year increase. Earnings per share came in at 20 cents, ahead of the 12 cents consensus.
Subscriber growth was a key driver, climbing 38% year-over-year to 2.4 million. Gross margin stood at 73%, with operating cash flow of $109.1 million and free cash flow of $50.1 million.
CEO Andrew Dudum highlighted <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45226761/whats-going-on-with-hims-hers-stock-tuesday">strong momentum</a> entering 2025, citing growing demand for accessible and personalized healthcare. The company reaffirmed full-year revenue guidance of $2.3 billion to $2.4 billion and projected at least $6.5 billion in annual revenue by 2030, alongside $1.3 billion in adjusted EBITDA.
Despite a slightly conservative second-quarter revenue outlook of $530–$550 million, compared to the expected $564.56 million estimates, investor enthusiasm remains high as the company shows progress scaling its platform.
Read Also: <a href="https://www.benzinga.com/personal-finance/25/05/45256758/that-cake-is-already-baked-says-bill-ackman-warning-u-s-china-tariff-war-is-driving-companies-out-of-china-for-good">That Cake Is Already Baked,&#8217; Says Bill Ackman, Warning U.S.-China Tariff War Is Driving Companies Out Of China For Good</a>
<h2 class="wp-block-heading">How To Buy HIMS Stock</h2>
By now you're likely curious about how to participate in the market for Hims &amp; Hers Health &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, HIMS has a 52-week high of $72.98 and a 52-week low of $11.64.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Stock Soars 32% Since Tuesday On Strong Q1 Earnings And Robust Outlook

U.S. Treasury Secretary Scott Bessent told lawmakers on Wednesday that the United States should position itself as the global leader in digital assets, reinforcing the administration's support for establishing a clear <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44850021/fed-chair-powell-says-crypto-and-banking-rules-will-loosen-as-sector-matures">regulatory framework for the crypto industry</a>.
What Happened: During testimony before the House Financial Services Committee, Bessent <a href="https://www.theblock.co/post/353482/treasury-secretary-scott-bessent-says-us-should-be-the-premier-destination-for-digital-assets?utm_source=rss&amp;utm_medium=rss">said</a>, "We believe that the United States should be the premier destination for digital assets," adding that Congress is making progress toward shaping a solid market structure that could help promote American standards globally.
Bessent, confirmed to the Treasury post in January after being nominated by President Donald Trump, has been vocal in backing crypto as a permanent fixture in the financial system. 
He also serves on the President's Working Group on Digital Asset Markets, created through an executive order signed earlier this year.
Although much of Wednesday's hearing centered on trade and tariff policy, lawmakers also discussed ongoing efforts to regulate crypto markets. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45248184/bitcoin-is-no-longer-just-digital-gold-native-staking-yield-are-redefining-its-role-says-core-dao">Bitcoin Is No Longer Just Digital Gold — Native Staking, Yield Are Redefining Its Role, Says Core DAO</a>
House Republicans recently circulated a draft bill that proposes dividing oversight responsibilities between the Commodity Futures Trading Commission (CFTC) and the Securities and Exchange Commission (SEC), while also laying out disclosure requirements for digital asset issuers.
Why It Matters: Tensions over crypto legislation have grown in recent months, particularly among Democrats, who remain concerned about Trump's personal involvement in the space.
His launch of a meme coin and the debut of a stablecoin by his affiliated firm, <a href="https://www.benzinga.com/news/legal/25/04/45077156/trump-affiliated-world-liberty-financial-defies-ethics-concerns-raises-550-million">World Liberty Financial</a>, have raised ethical questions about influence and conflicts of interest.
Some Democratic members walked out of a scheduled crypto hearing earlier this week in protest. 
However, others, including Rep. Angie Craig (D-Minn.), opted to remain, calling for bipartisan collaboration on digital asset policy.
Meanwhile, a separate Senate bill aimed at regulating stablecoins is due for a vote on Thursday but has encountered pushback. Over the weekend, a group of Democratic Senators, among them Ruben Gallego, Raphael Warnock, Mark Warner, and Lisa Blunt Rochester, voiced opposition to the current version, citing unresolved legal and operational issues.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45242623/ripple-commits-25m-to-us-teachers-and-classrooms-via-rlusd-stablecoin">Ripple Commits $25M To US Teachers And Classrooms Via RLUSD Stablecoin</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Treasury Sec Scott Bessent: US Should Be The 'Premier Destination For Digital Assets'

RBC Capital analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Outperform and lowers the price target from $182 to $172.

JAZZ

RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $172

Lina Khan, the former Federal Trade Commission chair under Joe Biden, is warning that dialing back enforcement at the agency will result in a surge of deceptive "Made in USA" claims, putting honest American businesses at a disadvantage.
&#8220;Made in USA&#8221; rules under pressure
On April 26, Khan <a href="https://x.com/linamkhan/status/1916198508404654385">responded</a> to a <a href="https://x.com/dieworkwear/status/1916173529781047637">post</a> on X from menswear writer Derek Guy, who pointed out that the FTC has strict standards for labeling products as "Made in America," and that violations can carry serious fines, though many go undetected. "If you see fraud, you can report it to the FTC with a simple email," he said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The first Trump administration was famously weak when it came to policing Made in USA fraud. <a href="https://t.co/G9anR7ev2j">https://t.co/G9anR7ev2j</a> Thanks to <a href="https://twitter.com/ChopraUSA?ref_src=twsrc%5Etfw">@ChopraUSA</a>, we finalized a rule so that firms lying about their products being made in America now face fines. Gutting consumer protection enforcement… <a href="https://t.co/ToeDI8ulAF">https://t.co/ToeDI8ulAF</a>
&mdash; Lina Khan (@linamkhan) <a href="https://twitter.com/linamkhan/status/1916198508404654385?ref_src=twsrc%5Etfw">April 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
Khan took the opportunity to contrast current enforcement efforts with those during President Donald Trump's first term. "The first Trump administration was famously weak when it came to policing Made in USA fraud," she wrote, linking to a 2019 <a href="https://www.nytimes.com/2019/04/17/us/politics/made-in-america-ftc-trump.html">New York Times</a> article detailing how Trump's appointees to the FTC blocked penalties against companies caught mislabeling imported goods.
Khan praised Rohit Chopra, a fellow Democrat and former FTC commissioner, for helping finalize a rule that empowers the FTC to fine companies for falsely claiming their products are made in America.
"Thanks to @ChopraUSA, we finalized a rule so that firms lying about their products being made in America now face fines," Khan said. "Gutting consumer protection enforcement means Made in USA fraud will skyrocket, punishing honest American businesses."
Trending: Donald Trump just announced a $500 billion AI infrastructure deal — <a href="https://www.benzinga.com/money/seize-a-share-while-you-still-can-in-the-2-trillion-entertainment-market-with-elf-labs-at-just-2-25-share">here's how you can invest in the entertainment market's next big disruptor at $2.25 per share</a>.
<h2 class="wp-block-heading">Trump Tightens Grip on the FTC</h2>
Since returning to White House in January, Trump has moved aggressively to <a href="https://www.benzinga.com/news/25/02/44005304/trumps-executive-order-could-reshape-fed-sec-and-other-financial-regulators">assert control over independent agencies</a>, including the FTC. In March, he fired Democratic commissioners Alvaro Bedoya and Rebecca Kelly Slaughter. Both claimed the move was illegal and have sued the Trump administration.
"The president just illegally fired me. This is corruption plain and simple," Bedoya <a href="https://x.com/BedoyaFTC/status/1902105345545113607">wrote on X</a>.&nbsp;
With those seats vacated, Trump installed allies, including current FTC Chair <a href="https://www.benzinga.com/markets/24/12/42428224/bitcoin-ethereum-dogecoin-mirror-stock-declines-ahead-of-crucial-inflation-data-release-top-analyst-says-buy-the-dip-predicts-275k-btc-target">Andrew Ferguson</a>. Critics say these moves undermine the FTC's independence and open the door to industry influence.
<h2 class="wp-block-heading">Doubts about Ferguson's intentions</h2>
Chair Ferguson initially calmed some fears when he <a href="https://www.ftc.gov/news-events/news/press-releases/2025/02/ftc-chairman-andrew-n-ferguson-announces-ftc-dojs-joint-2023-merger-guidelines-are-effect">announced</a> the FTC would continue using the 2023 Merger Guidelines developed under Khan's leadership. That decision was seen by some as a win for antitrust advocates, especially those aligned with the "New Brandeis" movement.
See Also: Shark Tank's Kevin O'Leary called Missing Ring his biggest mistake — Don't repeat history—<a href="https://www.benzinga.com/money/big-tech-has-spent-billions-acquiring-ai-smart-home-startups-one-company-stands-to-benefit-and-has-already-made-10-million">invest in RYSE at just $1.90/share.</a>
But legal experts remain wary. "It is possible to get the right answer for the wrong reason," wrote law professor Darren Bush in a February column for <a href="https://www.thesling.org/is-the-new-ftc-chairman-truly-pro-enforcement/">The Sling</a>. He noted that Ferguson had previously pledged to end "Lina Khan's war on mergers" and accused her of politicizing antitrust enforcement.
Ferguson has also taken steps to align the FTC more closely with Trump's broader agenda, including ending the agency's diversity programs and blocking political appointees from participating in events hosted by organizations critical of Trump. Meanwhile, his resistance to investigating sectors outside Big Tech, such as Bedoya's call to probe rising egg prices, has raised further concerns, according to Bush.
As Khan warns, pulling back on consumer protections could create a flood of dishonest marketing, with consequences for the very companies that follow the rules.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.30/share!</a></li>
</ul>
Image: Shutterstock

Lina Khan Warns That Weakening Consumer Protections Will Backfire: 'Made In USA Fraud Will Skyrocket, Punishing Honest American Businesses'

<a href="https://techcrunch.com/2025/05/07/servicenow-acquires-data-world-two-months-after-acquiring-moveworks/">https://techcrunch.com/2025/05/07/servicenow-acquires-data-world-two-months-after-acquiring-moveworks/</a>

'ServiceNow acquires Data.World months after snatching up Moveworks'- Techcrunch

Baird analyst Timothy Wojs maintains AZEK Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZEK#NYSE">AZEK</a>) with a Neutral and raises the price target from $48 to $52.

AZEK

Baird Maintains Neutral on AZEK Co, Raises Price Target to $52

RBC Capital analyst Sabahat Khan maintains Jacobs Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>) with a Outperform and raises the price target from $152 to $154.

RBC Capital Maintains Outperform on Jacobs Solutions, Raises Price Target to $154

RBC Capital analyst Mike Dahl maintains JELD-WEN Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JELD#NYSE">JELD</a>) with a Underperform and lowers the price target from $5 to $2.

JELD

RBC Capital Maintains Underperform on JELD-WEN Holding, Lowers Price Target to $2

Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) shares are trading<a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener"> lower on Wednesday.</a>
On Tuesday, Upstart reported first-quarter earnings of 30 cents per share, which beat the analyst <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45237407/upstart-stock-drops-after-q1-results-details" rel="noreferrer noopener">consensus estimate of 17 cents</a>.
Quarterly revenue was $213.37 million. That&#8217;s up from $127.79 million in the same period last year. The company beat the consensus estimate of $199.49 million
Here are the key analysts&#8217; takes on the stock:
<ul>
<li>JPMorgan analyst Reginald L. Smith reiterated the Neutral rating on Upstart, lowering the price forecast from $79 to $64.</li>
<li>Piper Sandler analyst Arvind Ramnani maintained the Overweight rating, with a price forecast of $69.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43669769/upstarts-model-enhancements-propel-stock-up-after-q4-analyst-boosts-forecasts-fueling-optimism-for-2025-growth" rel="noreferrer noopener">Upstart Is A Good Fit For Fintech Growth Investors, Analyst Says</a>
JPMorgan: The analyst writes Upstart is gaining momentum from a flywheel effect—stronger repayment data is enhancing its ability to detect risk and fraud, which in turn drives higher loan approval rates and boosts overall volume.
Smith highlighted that he sees significant potential in the company's AI-driven lending platform, particularly as the loan funding environment improves.
The analyst also highlights Upstart's increasingly stable capital structure, noting that over half of its originations are now supported by committed capital partners.
The analyst notes that Upstart is refining its underwriting models by using "embeddings," a technique from natural language processing, to better detect risk patterns.
Per Smith, the company will share more updates on its AI advancements during its Analyst Day next week.
Piper Sandler: The analyst notes that average loan sizes rose slightly due to more super prime borrowers.
Upstart slightly raised its full-year revenue outlook—mainly from interest income—and increased its EBITDA margin guidance by 100 basis points. While the forecast assumes stable economic conditions, management flagged rising uncertainty and inflation as key risks that could affect credit performance.
Despite meeting expectations on fee-based revenue, the analyst highlighted that stock fell results lag buyside hopes and concerns grow over macro risks and widening credit spreads.
Ramnani is modeling revenue growth of +58.9% in FY25 and +25.8% in FY26.
Price Action: UPST shares are trading lower by 10.29% to $45.86 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45257429/michael-saylor-calls-bitcoin-the-corporate-survival-strategy-for-96-of-companies" target="_blank" rel="noreferrer noopener">Michael Saylor Calls Bitcoin The &#8216;Corporate Survival Strategy&#8217; For 96% of Companies</a></li>
</ul>
Image: Shutterstock

Equities

Markets

Trading Ideas

UPST

Upstart Stock Drops Despite Q1 Beat: Analysts Highlight AI Progress, Warn Of Inflation Risks

RBC Capital analyst Matthew Hedberg maintains Gen Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>) with a Sector Perform and raises the price target from $28 to $30.

RBC Capital Maintains Sector Perform on Gen Digital, Raises Price Target to $30

AMZN

Amazon Web Services Joins ServiceNow's Workflow Data Network Ecosystem To Unlock Real-time Insights, Increase Ai-driven Actions, And Create Seamless Enterprise Data Unification

Press Releases

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation

MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity

MIRA

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Athira Pharma

CalciMedica

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cingulate

Cocrystal Pharma

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Durect

Gelteq

Hoth Therapeutics

IGC Pharma

Iterum Therapeutics

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lexaria Bioscience

Lipocine

NRX Pharmaceuticals

Pulmatrix

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Scilex Holding

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

Talphera

TherapeuticsMD

VYNE Therapeutics

Rodman & Renshaw

Ascendiant Capital

Screenshot 2024-10-02 at 5.44.40 PM

Biotech

Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game

Screenshot 2024-09-18 at 6.27.57 PM

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025

Screenshot 2024-09-04 at 6.19.41 PM

TELO

Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs

Screenshot 2024-08-26 at 4.53.37 PM

The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End

Screenshot 2024-07-25 at 6.08.16 PM

MIRA Pharmaceuticals (NASDAQ: MIRA) Reports Promising Pre-Clinical Trial Results For Mental Health Treatment, To Submit Investigational New Drug Application By End Of Year

Comments

Mira Pharmaceuticals

空売り

Mira Pharmaceuticals (NASDAQ:MIRA) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル